@ARTICLE{
author={Petzer Andreas L,...,Bogdanovic Andrija D,...,(broj koautora 20)},
year={2012},
title={High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients - final analysis of a randomized, multicenter, phase III trial},
journal={HAEMATOLOGICA-THE HEMATOLOGY JOURNAL},
volume={97},
number={10},
pages={1562-1569},
document_type={Article},
} 

@ARTICLE{
author={Petzer Andreas L,Fong Dominic,Lion Thomas,Dyagil Irina,Masliak Zvenyslava,Bogdanovic Andrija D,Griskevicius Laimonas,Lejniece Sandra,Goranov Stefan,Gercheva Liana,Stojanovic Aleksandar,Peytchev Dontcho,Tzvetkov Nikolay,Griniute Rasa,Oucheva Radka,Grubinger T,Kwakkelstein Marthin,Rancati Francesca,Gastl Guenther A,Wolf Dominik},
year={2011},
title={Pre-treated CML Patients in chronic phase (CP) not achieving at least a major cytogenetic remission (MCyR) after imatinib high dose (HD) induction (800 mg/day, 6 months) are at high risk of progression after dose reduction - Sub-analyses from the CELSG phase III "ISTAHIT" trial},
journal={ONKOLOGIE},
volume={34},
number={},
pages={264-264},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Petzer Andreas L,...,Bogdanovic Andrija D,...,(broj koautora 20)},
year={2010},
title={Significantly higher and more rapid cytogenetic and molecular responses can be achieved in pre-treated chronic phase CML patients with high doses of Imatinib as induction therapy (800 mg/day, 6 months) - final results of a Phase III CELSG CML11 "ISTAHIT" TRIAL},
journal={ONKOLOGIE},
volume={33},
number={},
pages={83-83},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Petzer Andreas L,...,Bogdanovic Andrija D,...,Stojanovic Aleksandar,...,(broj koautora 20)},
year={2010},
title={High Dose Imatinib Induction (800 Mg/day, 6 Months) Induces Significantly Higher Cytogenetic and Molecular Responses in Pre-treated Chronic Phase CML -phase III Celsg 'istahit' Trial - First Results},
journal={HAEMATOLOGICA-THE HEMATOLOGY JOURNAL},
volume={95},
number={},
pages={0133-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Petzer Andreas L,Wolf Dominik,Fong Dominic,Lion Thomas,Dyagil Irina,Masliak Zvenyslava,Bogdanovic Andrija D,Griskevicius Laimonas,Lejniece Sandra,Goranov Stefan,Gercheva Liana,Stojanovic Aleksandar,Peytchev Dontcho,Tzvetkov Nikolay,Griniute Rasa,Oucheva Radka,Ulmer Hanno,Kwakkelstein Marthin,Rancati Francesca,Gastl Guenther A},
year={2010},
title={High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study},
journal={HAEMATOLOGICA-THE HEMATOLOGY JOURNAL},
volume={95},
number={6},
pages={908-913},
document_type={Article},
} 

@ARTICLE{
author={Petzer Andreas L,Boskovic Darinka V,Gastl Guenther A},
year={2008},
title={Celsg Cml 11 "Istahit" Phase Iii Study - Planned Interim Analysis: High Doses Of Imatinib Mesylate (800mg/Day) Significantly Improve Rates Of Major And Complete Cytogenetic Remissions (Mcr, Ccr) In Pretreated Ph+/Bcr-Abl(+) Cml Patients In Chronic Phase},
journal={BLOOD},
volume={112},
number={11},
pages={406-406},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Petzer Andreas L,Wolf Dominik,Fong Dominic,Lion Thomas,Dyagil Irina,Masliak Zvenyslava,Boskovic Darinka V,Griskevicius Laimonas,Lejniece Sandra,Spasov Emil,Gercheva Liana,Stojanovic Aleksandar,Peytchev Dontcho,Tzvetkov Nikolay,Griniute Rasa,Stanchev Atanas,Kwakkelstein Martin,Ulmer Hanno,Gastl Guenther A},
year={2007},
title={Multicenter, randomized, phase III study comparing imatinib (Glivec) standard dose (400 mg/d) with imatinib high dose induction (800 mg/d) followed by imatinib maintenance (400 mg/d) in patients with pretreated Ph+/BCR-ABL(+) CML in chronic phase - Results from the first planned interim analysis (CELSG-CML 11 ISTAHIT study)},
journal={BLOOD},
volume={110},
number={11},
pages={317A-317A},
document_type={Meeting Abstract},
}